Autologous muscle‐derived cells for the treatment of female stress urinary incontinence: A 2‐year follow‐up of a polish investigation

Stangel-Wójcikiewicz, Klaudia; Jarocha, Danuta; Piwowar, Monika; Jach, Robert; Uhl, Tadeusz; Basta, Antoni; Majka, Marcin

doi:10.1002/nau.22404

Cited by 84 publications

(65 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was the only study to inject 2 types of stem cells (myoblasts and fibroblasts) and to use the highest doses (1.4-6.06x107 fibroblasts and 1x107-3x107 myoblasts). Stangel [7] also obtained good outcomes with cure obtained by 50% and partial improvement by 25%). Sebe [1] observed 25% dry patients (83% with improvement), Blaganje [9] 13.5% with cure, 78.4% with improvement, and Carr [8] 12.5% with cure and 62.5% with improvement.…”

Section: Results: Safety Effectiveness and Efficiencymentioning

confidence: 83%

“…All studies excluded urge incontinence or abnormal detrusor activity except for the study by Lee [5], which included 9 patients with mixed UI. However, in SUI, some only required that the patient had stress urinary incontinence (regardless of severity) [2,5,7,8] whereas others include only patients with SUI due to inherent sphincter weakness or at least exclude patients with urethral hypermobility > 45⁰ [1,3,9,10]. Nonetheless, it appears that the purpose of stem cells is to regenerate damaged sphincters, rather than to provide urethral support; in fact, some studies exclude patients with prolapse [2,4,9].…”

Section: Inclusion Criteria Of Patients In Studies For the Treatment mentioning

confidence: 99%

“…Nonetheless, it appears that the purpose of stem cells is to regenerate damaged sphincters, rather than to provide urethral support; in fact, some studies exclude patients with prolapse [2,4,9]. In most studies, this treatment was tested in patients who had experienced previous failure of conservative treatment, including electrical stimulation [2,5,[7][8][9]. One study [3] began with rehabilitation treatment, then performed stem-cell injection, and later performed electrical stimulation for 4 weeks; according to the author this favored stem-cell integration and regeneration.…”

Section: Inclusion Criteria Of Patients In Studies For the Treatment mentioning

confidence: 99%

“…Both also reported that all doses were equally safe. Another study [7] concluded that a small amount of cells (1x10 6 ) was sufficient to achieve continence in some patients.…”

Section: Number Of Stem Cell Implantedmentioning

confidence: 99%

See 3 more Smart Citations

Current Controversies in Stem-Cell Treatment of Urinary Incontinence in Women

Ferrer¹,

Machado-Linde²,

Prieto-Sánchez³

et al. 2014

Int J Gynecol Clin Pract

View full text Add to dashboard Cite

Background: Urinary incontinence (UI) is a major cause of morbidity in the world and is believed to affect up to 46% of the female population Our objective was to analyze the papers that describe stem-cell treatments for UI in women. Methods: We performed a systematic review of the literature from 1946 to date that reports on clinical trials that use stem cells to treat women with urinary incontinence. Results: Nine articles (7 observational and 2 randomized studies) met the inclusion criteria. No major adverse effects were observed in any of the studies. However, the efficacy results differ widely, as the methodology used for studies was very different, as described below. Conclusion: Stem-cell therapy is promising but still experimental, and further study is needed to identify certain factors. These facts include the ideal type of patient eligible for treatment (apparently those in whom intrinsic urethral dysfunction predominates), and to determine if treatment should be isolated or combined with other cells or procedures, which are the optimal doses and if it is a cost effective procedure.

show abstract

Section: Results: Safety Effectiveness and Efficiencymentioning

confidence: 83%

Section: Inclusion Criteria Of Patients In Studies For the Treatment mentioning

confidence: 99%

Section: Inclusion Criteria Of Patients In Studies For the Treatment mentioning

confidence: 99%

“…Both also reported that all doses were equally safe. Another study [7] concluded that a small amount of cells (1x10 6 ) was sufficient to achieve continence in some patients.…”

Section: Number Of Stem Cell Implantedmentioning

confidence: 99%

See 2 more Smart Citations

Current Controversies in Stem-Cell Treatment of Urinary Incontinence in Women

Ferrer¹,

Machado-Linde²,

Prieto-Sánchez³

et al. 2014

Int J Gynecol Clin Pract

View full text Add to dashboard Cite

show abstract

“…Cell therapy for urinary incontinence is rapidly moving from the preclinical to the clinical testing stages. As such, the major emphasis of testing has turned to optimization of the cell types and doses and, especially, of its safety [18][19][20]. Most preclinical studies have focused on the functional efficacy, sphincter regeneration, and mechanism of action [18].…”

Section: Discussionmentioning

confidence: 99%

The Dose-Effect Safety Profile of Skeletal Muscle Precursor Cell Therapy in a Dog Model of Intrinsic Urinary Sphincter Deficiency

Williams

Eckman

Dean

et al. 2015

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Locally injected skeletal muscle precursor cells (skMPCs) integrate into and restore the muscle layers, innervation, vasculature, and function of the sphincter complex in animal models of intrinsic urinary sphincter deficiency (ISD). The goal of the present study was to test the dose-effect safety profile of skMPC therapy in a dog model of ISD. Sphincter deficiency was created in 20 adult female dogs by surgically removing the skeletal muscle layer of the urinary sphincter complex. skMPCs isolated from the hind leg were expanded in culture and injected 4 weeks later into the sphincter complex at a dose of 25 million cells (n = 5), 50 million cells (n = 5), or 100 million cells (n = 5) per milliliter in a 2-ml volume. Five dogs received no sphincter injection. The measures of maximal sphincter pressure, complete blood count, and blood chemistry were performed monthly until their sacrifice at 9 months. At that point, full necropsy was performed to assess the safety of the skMPC injections. Injection of different doses of cells had no effects on the body weight, blood cell count, or kidney or liver function test results (p > .05 among the skMPC doses). Some incidental pathologic features were found in the lower urinary tract in all groups and were most likely associated with repeat catheterization. The maximal urinary sphincter pressure was higher in the 50 million cells per milliliter treatment group than in the other experimental groups (p < .05). The findings of the present study have confirmed that urinary sphincter injection of skMPCs results in no significant local or systemic pathologic features within the dose range that improves sphincter pressures. STEM CELLS TRANSLATIONAL MEDICINE 2015;4:286-294

show abstract

A systematic review of stem cell therapy treatment for women suffering from stress urinary incontinence

Klapper-Goldstein

Tamam

Sade

et al. 2021

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Background Stem cell therapy (SCT) is used for regeneration of injured tissues. This seems a novel promising strategy for restoring urethral sphincter function in patients with stress urinary incontinence (SUI). Objective To summarize the clinical trials available to date on SCT for treatment of SUI in women. Search strategy PubMed, Cochrane Library, Scopus and Embase. Selection criteria Prospective interventional case series, randomized prospective interventional study and prospective cohort study assessing women aged 18 years and over diagnosed with SUI and treated by SCT were included. The quality of studies was finally assessed using the JBI Critical Appraisal Checklists according to the PRISMA guidelines. Data collection and analysis Nineteen studies (n = 773 patients) were selected for final analysis. These were conducted worldwide between the years 2005 and 2016. Although different cell types were used, general processing steps were similar. The follow‐up period ranged between 6 weeks and 6 years and included common subjective and objective evaluation tools. Results Overall, the studies imply that SCT for treatment of SUI is a safe and effective treatment. Conclusion In our opinion, the initial results of SCT for the treatment of SUI seem promising. Standardization and validation of this treatment modality is required before it can be recommended for routine use.

show abstract

Autologous muscle‐derived cells for the treatment of female stress urinary incontinence: A 2‐year follow‐up of a polish investigation

Abstract: Stem cell therapy promises to become a minimally invasive method for the regeneration of the urethral rhabdosphincter muscle. Injecting a small number of cells does not preclude obtaining the desired therapeutic result.

Cited by 84 publications

References 24 publications

Current Controversies in Stem-Cell Treatment of Urinary Incontinence in Women

Current Controversies in Stem-Cell Treatment of Urinary Incontinence in Women

The Dose-Effect Safety Profile of Skeletal Muscle Precursor Cell Therapy in a Dog Model of Intrinsic Urinary Sphincter Deficiency

A systematic review of stem cell therapy treatment for women suffering from stress urinary incontinence

Contact Info

Product

Resources

About